Highlights

  • June-quarter Operating Cash Flow was positive AUD 1.1 million.
  • Cash reached AUD 19.9 million at 30 June, with no debt.
  • Annual Recurring Revenue run-rate reached AUD 23.5 million.
  • Two five-year subscription agreements carried combined contract value of AUD 4.5 million.

Mach7 Technologies Limited (ASX:M7T) develops software that allows hospitals and healthcare networks to store, share, route and view medical images across clinical systems. Its FY26 update illustrated a transition from operational restructuring to new customer deployments. The financial picture is mixed: subscription additions and a positive final-quarter cash result sit alongside revenue pressure from delayed Capital transactions. Understanding the difference between signed contract value, recurring run-rate and receipts is essential when assessing that transition.

Hospital Agreements Add Future Contract Value

During the June 2026 quarter, Mach7 announced a five-year subscription expansion licence with an established academic medical-centre customer carrying AUD 2.8 million in total contract value. It also signed a five-year AUD 1.7 million eUnity Subscription Agreement with AMRADNET. Combined, the agreements represented AUD 4.5 million in total contract value across their contractual lives, not AUD 4.5 million in immediate cash receipts or annual revenue. Their significance lies in extending the contracted software base, with revenue recognition and collections dependent on terms and deployment activity.

Recurring Run-Rate and Cash Position

The annual recurring revenue run-rate stood at AUD 23.5 million on 30 June 2026, up 7.6% in constant currency from a year earlier. This is a point-in-time annualised measure, not the same as audited FY26 revenue. The company reported AUD 1.1 million of positive operating cash flow in the fourth quarter, with closing cash of AUD 19.9 million compared with AUD 19.2 million at the end of March. It reported no debt. These measures provided evidence of near-term financial improvement, but one positive quarter does not establish that cash generation will remain positive.

Flamingo, eUnity and Hospital Access

Mach7 reported that UnityPoint Health had gone live with its Flamingo Orchestration product, marking a production deployment rather than a future aspiration. The company also added a Partnership with Howard Medical, describing indirect access to more than 3,700 hospitals. Its eUnity product appeared in the Epic Connection Hub, an interoperability milestone intended to simplify access within the Epic environment. The number of hospitals available through a partner is not a count of customer contracts won. Commercial outcomes depend on conversion from potential access to signed deployments and subsequent recurring fees.

Revenue Conversion Remains the Central Test

Management reaffirmed at the July quarterly update its expectation that FY26 revenue would be approximately 15% below FY25 because capital deal conversions had been delayed. Operating expenses were expected to be approximately 10% lower. Subsequent FY26 reporting and the October 2026 Annual Report offer the fuller accounting record, while the June operational update explains the contracting and cash-flow direction. Delayed procurement decisions, hospital integration requirements and implementation timelines remain significant uncertainties. Subscription agreements improve contracted visibility but do not eliminate the timing difference between orders, recognised revenue and cash collections.

Key Insights

Mach7’s June-quarter update combined a higher recurring-revenue run-rate, new subscription contracts and an improved cash position. Its product deployments provide operational milestones, while the timing of hospital procurement, recognised revenue and sustained cash generation remains central to execution.